NO20011371L - Kjemokinreseptorantagonist og cyklosporin i kombinert terapi - Google Patents

Kjemokinreseptorantagonist og cyklosporin i kombinert terapi

Info

Publication number
NO20011371L
NO20011371L NO20011371A NO20011371A NO20011371L NO 20011371 L NO20011371 L NO 20011371L NO 20011371 A NO20011371 A NO 20011371A NO 20011371 A NO20011371 A NO 20011371A NO 20011371 L NO20011371 L NO 20011371L
Authority
NO
Norway
Prior art keywords
cyclosporin
receptor antagonist
chemokine receptor
pharmaceutical composition
combined therapy
Prior art date
Application number
NO20011371A
Other languages
English (en)
Other versions
NO20011371D0 (no
Inventor
Hermann-Joseph Grone
Peter J Nelson
Amanda Proudfoot
Timothy N C Wells
Original Assignee
Applied Research Systems
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Applied Research Systems filed Critical Applied Research Systems
Publication of NO20011371L publication Critical patent/NO20011371L/no
Publication of NO20011371D0 publication Critical patent/NO20011371D0/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/521—Chemokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Transplantation (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Det er beskrevet anvendelse av en kjemokin reseptorantagonist sammen med et cyklosporin til å fremstille en farmasøytisk sammensetning til å behandle eller forhindre avstøtning av transplanterte organer, vev eller celler. Nevnte farmasøytiske sammensetning for samtidig, separat eller sekvensiell anvendelse av dens aktive ingredienser i den ovenfor spesifiserte terapi er også beskrevet og krevd. Særlig er det eksperimentelt vist anvendelse av Met-RANTES sammen med cyklosporin A til å produsere en farmasøytisk sammensetning til behandling av renal alografttransplantatavstøtning.
NO20011371A 1998-09-18 2001-03-16 Kjemokinreseptorantagonist og cyklosporin i kombinert terapi NO20011371D0 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP98117697A EP1000626A1 (en) 1998-09-18 1998-09-18 Chemokine receptor antagonist and cyclosporin in combined therapy
PCT/EP1999/006844 WO2000016796A1 (en) 1998-09-18 1999-09-16 Chemokine receptor antagonist and cyclosporin in combined therapy

Publications (2)

Publication Number Publication Date
NO20011371L true NO20011371L (no) 2001-03-16
NO20011371D0 NO20011371D0 (no) 2001-03-16

Family

ID=8232654

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20011371A NO20011371D0 (no) 1998-09-18 2001-03-16 Kjemokinreseptorantagonist og cyklosporin i kombinert terapi

Country Status (23)

Country Link
US (1) US6902728B1 (no)
EP (2) EP1000626A1 (no)
JP (1) JP2003519082A (no)
KR (1) KR100613950B1 (no)
CN (1) CN1177613C (no)
AR (1) AR021810A1 (no)
AT (1) ATE227582T1 (no)
AU (1) AU766595B2 (no)
BR (1) BR9913846A (no)
CA (1) CA2344370A1 (no)
DE (1) DE69903964T2 (no)
DK (1) DK1113811T3 (no)
EA (1) EA003181B1 (no)
EE (1) EE04705B1 (no)
ES (1) ES2186411T3 (no)
HK (1) HK1041225B (no)
IL (2) IL141899A0 (no)
NO (1) NO20011371D0 (no)
PT (1) PT1113811E (no)
SI (1) SI1113811T1 (no)
UA (1) UA60379C2 (no)
WO (1) WO2000016796A1 (no)
ZA (1) ZA200101909B (no)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7259136B2 (en) 1999-04-30 2007-08-21 Amylin Pharmaceuticals, Inc. Compositions and methods for treating peripheral vascular disease
US6740636B2 (en) 2000-07-31 2004-05-25 Schering Aktiengesellschaft Non-peptide CCR1 receptor antagonists in combination with cyclosporin A for the treatment of heart transplant rejection
LT5132B (lt) 2000-07-31 2004-05-25 Schering Aktiengesellschaft Nepeptidiniai ccr1 receptorių antagonistai derinyje su ciklosporinu a širdies transplanto atmetimui gydyti
JP5624884B2 (ja) 2007-08-02 2014-11-12 ノビミューンエスアー 抗ｒａｎｔｅｓ抗体およびその使用の方法
WO2017040520A1 (en) 2015-08-31 2017-03-09 Hitachi Chemical Co., Ltd. Molecular methods for assessing urothelial disease
DE112016003951T5 (de) * 2015-08-31 2018-05-30 City Of Sapporo Molekulare verfahren zur beurteilung von komplikationen nach einer nierentransplatation

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996017935A2 (en) * 1994-12-08 1996-06-13 Glaxo Group Limited Rantes peptide and fragments and compositions comprising it for treatment of inflammation
EP0845994A1 (en) * 1995-08-09 1998-06-10 Schering Corporation Combined use of interleukin-10 and cyclosporin for immunosuppression therapy
WO1998006703A1 (en) * 1996-08-14 1998-02-19 Warner-Lambert Company 2-phenyl benzimidazole derivatives as mcp-1 antagonists
WO1998006751A1 (en) * 1996-08-16 1998-02-19 Research Corporation Technologies, Inc. Mcp-3, rantes and mip-1alpha receptor antagonists

Also Published As

Publication number Publication date
EE04705B1 (et) 2006-10-16
KR20010075060A (ko) 2001-08-09
CN1177613C (zh) 2004-12-01
UA60379C2 (uk) 2003-10-15
IL141899A0 (en) 2002-03-10
DE69903964D1 (en) 2002-12-19
SI1113811T1 (en) 2003-04-30
KR100613950B1 (ko) 2006-08-18
EA200100366A1 (ru) 2001-08-27
ATE227582T1 (de) 2002-11-15
CN1319021A (zh) 2001-10-24
NO20011371D0 (no) 2001-03-16
IL141899A (en) 2007-12-03
ES2186411T3 (es) 2003-05-01
EP1000626A1 (en) 2000-05-17
HK1041225A1 (en) 2002-07-05
EP1113811A1 (en) 2001-07-11
ZA200101909B (en) 2001-09-11
EP1113811B1 (en) 2002-11-13
EA003181B1 (ru) 2003-02-27
US6902728B1 (en) 2005-06-07
AR021810A1 (es) 2002-08-07
CA2344370A1 (en) 2000-03-30
BR9913846A (pt) 2001-06-05
HK1041225B (zh) 2005-04-22
EE200100159A (et) 2002-08-15
AU766595B2 (en) 2003-10-16
DE69903964T2 (de) 2003-03-27
JP2003519082A (ja) 2003-06-17
PT1113811E (pt) 2003-03-31
WO2000016796A1 (en) 2000-03-30
AU6191499A (en) 2000-04-10
DK1113811T3 (da) 2003-03-10

Similar Documents

Publication Publication Date Title
ATE291901T1 (de) Neue omeprazole und (s)-omeprazole zusammensetzung
GB2357969A (en) Improvements in or relating to the treatment of lesions
GR3030924T3 (en) Selective system scan for multizone radiotelephone subscriber units.
DE60031793D1 (de) Doxorubicin- und daunorubicin-enthaltende, zytotoxische mittel und deren therapeutische anwendung
EP1072273A4 (en) VASKULARISIERUNGSINHIBITOREN
NO20035434D0 (no) Behandling eller profylakse av transplantasjonsavst degree tning av insulinproduserende celler
HUS1900041I1 (hu) Treoszulfán alkalmazása betegek csontvelõ- és vér õssejt-transzplantáció elõtti kondicionálására
NO20011371L (no) Kjemokinreseptorantagonist og cyklosporin i kombinert terapi
Frank et al. Clinical management: comparison of biobrane, porcine, and human allograft as biologic dressings for burn wounds
ATE269098T1 (de) Verfahren zur vorbeugung von durch zyklosporine oder tacrolimus verursachter nierenvergiftung
JP2003519082A5 (no)
FR2811229B1 (fr) Utilisation d'un polysaccharide excrete par l'espece vibrio diabolicus en cicatrisation osseuse
BR0115364A (pt) Tratamento de disfunção sexual
Hoffler et al. Nitrendipine in hypertension that is difficult to control
EP0349589A4 (en) PHARMACOLOGICALLY ACTIVE CHOLINERGE PREPARATIONS AND METHOD FOR THE PRODUCTION AND THEIR USE FOR TREATING DISEASES.
Herz Benzodiazepine prescribing in a community in crisis
Benmeir et al. Use of buried skin implants after recurrent failure of conventional skin grafting in a massive burn: the renewal of an old technique
JPS5738715A (en) Medical composition having activity of prohibiting artery wall from thickening
DE69931148D1 (de) Behandlung von hiv infektionen
UA48986C2 (uk) Препарат для лікування серцево-судинних захворювань'кардіофіт"
Lundell et al. Omeprazole or Ranitidine in the Short-term Treatment of Reflux Oesophagitis-Results on Healing and Relapse
BENNETT et al. The role of aggressive surgical treatment in the severely burned patient
HISANO et al. Experimental use of freeze-dried dura
Anderson The dilemma of Crohn's disease: management of the posterior wound after coloproctectomy
Matarasso et al. Relation Between Gengival Overgrowth and Cyclosporin (CyA) Blood Levels in Renal Transplanted Patients

Legal Events

Date Code Title Description
CREP Change of representative

Representative=s name: ONSAGERS AS, POSTBOKS 6963 ST OLAVS PLASS, 0130 OS

FC2A Withdrawal, rejection or dismissal of laid open patent application